Evidence map›Paper›PMID 19398034›Full record

ReviewProgress in retinal and eye research2009

Functional roles of bestrophins in ocular epithelia.

Alan D Marmorstein, Harold E Cross, Neal S Peachey

Open access · greenAbstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 132 citations in OpenAlex.

  1. Article
  2. Review of the clinical electrooculogram - Part 1: Mechanism of the Light-Rise.Documenta ophthalmologica. Advances in ophthalmology · 2026
    Review
  3. Gene Therapy Strategies for the Treatment of Bestrophinopathies.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alan D MarmorsteinDepartment of Ophthalmology and Vision Science, University of Arizona, Tucson, AZ 85711, USA. amarmorstein@eyes.arizona.edu
Harold E Cross
Neal S Peachey
University of Arizona · USCleveland Eye Clinic · US

Funding

BESTROPHIN AND RETINAL DISEASER01EY013160 · NEI · UNIVERSITY OF ARIZONA · PI MARMORSTEIN, ALAN D · 2000 to 2013
$5.0M
Bestrophin and Retinal DiseaseR56EY013160 · NEI · UNIVERSITY OF ARIZONA · PI MARMORSTEIN, ALAN D · 2009 to 2009
$378k
NEI NIH HHS EY13160NEI NIH HHS R01 EY013160NEI NIH HHS R56 EY013160
6 · The paper itself

Abstract

There are four members of the bestrophin family of proteins in the human genome, of which two are known to be expressed in the eye. The gene BEST1 (formerly VMD2) which encodes the protein bestrophin-1 (Best1) was first identified in 1998. Mutations in this gene have now been associated with four clinically distinguishable human eye diseases, collectively referred to as "bestrophinopathies". Over the last decade, laboratories have sought to understand how Best1 mutations could result in eye diseases that range in presentation from macular degeneration to nanophthalmos. The majority of our knowledge comes from studies that have sought to understand how Best1 mutations or dysfunction could induce the classical symptoms of the most common of these diseases: Best vitelliform macular dystrophy (BVMD). BVMD is a dominant trait that is characterized electrophysiologically by a diminished electrooculogram light peak with a normal clinical electroretinogram. This together with the localization of Best1 to the retinal pigment epithelium (RPE) basolateral plasma membrane and data from heterologous expression studies, have led to the proposal that Best1 generates the light peak, and that bestrophins are a family of Ca(2+) activated Cl(-) channels (CaCCs). However, data from Best1 knock-out and knock-in mice, coupled with the recent discovery of a recessive bestrophinopathy suggest that Best1 does not generate the light peak. Recently Best2 was found to be expressed in non-pigmented epithelia in the ciliary body. However, aqueous dynamics in Best2 knock-out mice do not support a role for Best2 as a Cl(-) channel. Thus, the purported CaCC function of the bestrophins and how loss of this function relates to clinical disease needs to be reassessed. In this article, we examine data obtained from tissue-type and animal models and discuss the current state of bestrophin research, what roles Best1 and Best2 may play in ocular epithelia and ocular electrophysiology, and how perturbation of these functions may result in disease.

Indexed as

AnimalsBestrophinsChloride ChannelsElectrophysiological PhenomenaEpitheliumEyeEye DiseasesEye ProteinsHumansMiceModels, AnimalMutationBEST1 protein, humanBEST2 protein, humanBestrophinsChloride ChannelsEye Proteins

Identifiers

PMID19398034
PMCPMC2740978
OpenAlexW2046497474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.